Berger, Raanan <br/><br/>
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  May 2008 
 - 3044-51 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-4079  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antigens, CD--metabolism<br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis Regulatory Proteins--metabolism<br/>Area Under Curve<br/>Dose-Response Relationship, Drug<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Hematologic Neoplasms--drug therapy<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Programmed Cell Death 1 Receptor